Urine Cytology Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

Market Synopsis of the Global Urine Cytology Market

Cytology is an emerging field in healthcare that plays an important role in the diagnosis of various diseases such as cancer, and chronic diseases. It involves the examination of cells of the body under a microscope. In urine cytology, urine specimen is collected from the patient to determine the functioning of the cells. The healthcare provider may recommend urine cytology examination if the patient has symptoms such as unexplained blood in the urine, burning and pain during urination. It is commonly used for the diagnosis of infection, inflammatory disease of the urinary tract, cancer of kidney, bladder, ureter, urethra, and others.

Rising prevalence of chronic diseases such as urinary tract infection, and cancer, increasing demand for urine tests, and the presence of key players in the market are important drivers that accelerate the growth of the market. Increasing demand for testing kits for home care is another key driver for the market growth. Additionally, increasing focus on diagnostic services in both the developing and developed regions across the globe also influences the growth of the market. Furthermore, replacement of manual instruments by automated ones in the hospitals and diagnostic centers also fuels the progress of the market. Although competition among key players in the market may act as a barrier for new entrants.

The global urine cytology market is expected to grow at a CAGR of 5.2% during the forecast period

Segments                                                                                                                                            

The global urine cytology market is segmented on the basis of product, indication, and end user.

On the basis of product, market is segmented into urine cytology instrument, urine cytology kit, and others. Product is further segmented into automated, and manual instrument.

On the basis of indication, the market is segmented into urinary infection, inflammatory disease, cancer, and others. Cancer is further segmented into kidney, bladder, ureter, and urethra.

On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, home care, and others.

Regional Analysis of the Global Urine Cytology Market                       

America acquires a leading position in the market for urine cytology, owing to the rising prevalence of various urinary tract infection, inflammatory disease, and cancer. Additionally, presence of key players manufacturing urine urology kits, and devices. The major players are engaged in various strategic approaches such as merger, acquisition, partnership, collaborations, and new product, and others to strengthen their position in the market. ThermoFischer Scientific, BD, and Sigma- Aldrich are 3 major players in the U.S. market.

 Europe is the second largest market for urine cytology owing to the availability of funds for research and development activities. Also, rising prevalence of cancer, increasing demand for diagnostic services and rising awareness about urine cytology for the diagnosis of diseases for urinary tract the market growth.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising prevalence of urinary tract infection which would act as a major risk factor for the growth of the market. Furthermore, rising awareness about the use of urine cytology for the diagnosis of urinary tract infection also influences the growth of the market. Additionally, changing lifestyle and rising geriatric population also drive the growth of the market. Furthermore, rising expenditure on healthcare by the developing countries in Asia Pacific also fuels the growth of the market.

The Middle East & Africa also show a steady rise in the market owing to high prevalence of chronic diseases such as infection, and cancer and improving healthcare infrastructure. The United Arab Emirates, and Saudi Arabia are the largest contributors to the growth of the market owing to the availability of specialty healthcare resources and demand for diagnostics devices, and test kits. Increasing demand for new treatment options for chronic diseases also influences the market growth in the Middle East & African countries. In Africa, the market shows positive growth owing to increasing prevalence of infectious diseases and demand for healthcare services in the developing and under developing countries.

Key Players in the Global Urine Cytology Market         

Some of the key players in this market are ThermoFischer Scientific (U.S.), BD (U.S.), Sigma- Aldrich (U.S.), Severn Biotech Limited (U.K), Bio-Techne (U.S), Laboratory Corporation of America Holdings (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and others.

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/urine-cytology-market-5116

         

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Injectable Drug Delivery Devices Market Growth and Restrain Factors Analysis By 2023

Market scenario:

Injectable drug delivery devices include an array of medical devices ranging from conventional syringes, needle-free injectors to auto and pen injectors. The demand for such devices has witnessed a rise in recent years on account of the mounting prevalence of chronic diseases across the globe. Market Research Future (MRFR) predicts the growth of the global injectable drug delivery devices market to be splendid at a CAGR of 11.5% over the forecast period of 2018-2023. The global injectable drug delivery devices market is likely to surpass a valuation of USD 31,900 Mn by the end of 2023.

The growth of the global injectable drug delivery devices market is sustained by the high prevalence of chronic diseases such as diabetes and cancer. Injectable drug delivery devices are used in the treatment of such medical conditions which spurs the demand for injectable drug delivery devices. In addition, owing to their use of use, injectable drug delivery devices are being progressively adopted. Other contributing factors to the growth of the market include key developments within the market as a result of R&D and clinical trials. Additionally, the rise in a number of FDA approvals also boosts the growth of the market. Introduction of advanced injectable drug delivery devices with superior functional capabilities is anticipated to reflect positively on the market growth.

Conversely, the growth of the global injectable drug delivery devices market might be restricted by the underlying risk of cross-contamination. Nevertheless, the proliferation of vaccination programs across underdeveloped countries provides lucrative growth opportunities for market expansion.

Segmentation

The global injectable drug delivery devices market has been segmented based on device, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.

By device, the global injectable drug delivery device market has been segmented into conventional injection devices and self-injection devices. The conventional injection devices segment has been further segmented into material, product, and utility. The self-injectable devices segment has been further segmented into needle-free injectors and pen systems and auto-injectors. The conventional injection devices segment commands the largest share of the global market.

By therapeutic application, the global injectable drug delivery device market has been segmented into autoimmune diseases, hormonal disorders, cancer, and others. The autoimmune diseases segment is the largest segment by therapeutic application.

By usage pattern, the global injectable drug delivery devices market has been segmented into curative and immunization. The curative segment is expected to be the fastest growing segment over the forecast period.

By site of delivery, the global injectable drug delivery devices market has been segmented into intramuscular, subcutaneous, and intradermal. The intramuscular segment is the largest segment.

By distribution channel, the global injectable drug delivery devices market has been segmented into hospital & retail pharmacies and online platforms. The hospitals & retail pharmacies segment is the largest segment while the online platform segment is expected to be the fastest growing segment by the end of 2023.

By facility of use, the global injectable drug delivery devices market has been segmented into hospitals and clinics, home care settings, and others.

Regional Analysis

By region, the global injectable drug delivery devices market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East and Africa (MEA).

The Americas is leading the global injectable drug delivery devices market. Expansion of the biotechnology industry, the surging prevalence of chronic diseases and a robust healthcare sector spur the growth of the market. Also, the region is a frontrunner in the incorporation of technologically advanced healthcare solutions which further accelerates the growth of the market.

Europe held the second largest share of the global market in 2017 and is likely to reach USD 13,074.3 Mn by the end of 2023. High adoption of advanced healthcare services coupled with extensive R&D efforts can be credited for the growth of the Europe market.

APAC market for injectable drug delivery devices market is expected to register the highest CAGR of 11.45 OVER TEH FORECAST period. High demand for advanced healthcare in rapidly growing economies drives the APAC market.

Lack of awareness and less exposure to primary healthcare services in the underdeveloped regions of the Middle East & Africa is expected to impede the growth of the market.

Competitive Landscape

The key players in the global injectable drug delivery devices market include Eli Lilly and Company, Antares Pharma, Inovio Pharmaceuticals Inc., Eisai Co. Ltd., Becton, Sanofi, Johnson & Johnson Services Inc., Novo Nordisk, AstraZeneca, F.Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Dickinson and Company, Novartis AG, and Mylan N.V.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/injectable-drug-delivery-devices-market-1211

        

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Verrucous Carcinoma Market - Granular Market Report and Review, 2018

Market Scenario:

Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer.  It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years. The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.

However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.

Key players

Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.

Segmentation

The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

On the basis of region, the global verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

It is estimated that North America dominated the global verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region

According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth. Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco.

Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.

The Middle East and Africa holds the least share in the global verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/verrucous-carcinoma-market-6367

         

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Age Related Macular Degeneration Market - Granular Market Report and Review, 2018

Market scenario:

As per the study offered by Market Research Future (MRFR), the global age related macular degeneration market is set to expand at a CAGR of 8.3% during the forecast period 2018 to 2023. The valuation of the market is predicted to grow from USD 1.37 Bn at the end of 2017 to 2.21 Bn by 2023-end. The growing patient pool of a geriatric population is leading the expansion of the market. It is estimated that AMD contributes significantly towards visual loss among the elderly population. In addition, the global aging population is expected to get doubled by the end of 2020. It is presumed to aid the proliferation of the age related macular degeneration market over the assessment period.

The expiry of drug patents for widely accepted branded drugs have opened new avenues of growth opportunities for the market participants. Investments are prognosticated to flow towards the development in the formulas of existing drugs for enhanced efficiency. In addition, expired drug patents have paved the way for a reduction in price points, thus, augmenting the global age related macular degeneration market.

The market is lucrative at present, and the rising awareness about the diseases is further expected to boost the growth trajectory of the age related macular degeneration market in the foreseeable future. On the flip side, unfavorable reimbursement policies and the high cost of drugs remain impediments to the market growth.

Competitive Dashboard:

Some of the key players profiled in this MRFR report are Regeneron Pharmaceutical Inc., Rxi Pharmaceuticals, F.Hoffmann-La Roche AG, Santen Pharmaceuticals and Bayer AG, Pfizer Inc., Allergan, Novartis AG, Bausch & Lomb Incorporated, and Alimera Sciences.

Market Segmentation:

By type, the global age related macular degeneration market has been segmented into wet AMD and dry AMD.

By stages, the age related macular degeneration market has been segmented into intermediate AMD, early AMD, and late AMD.

By age group, the global age related macular degeneration market has been segmented into above 75, above 60, and above 40.

By diagnosis & treatment, the age related macular degeneration market has been segmented into treatment and diagnosis.

By route of administration, the global age related macular degeneration market is segmented into intravitreal, intravenous, and others.

By end-user, the age related macular degeneration market has been segmented into hospitals & clinics, diagnostic centers, academic research institutes, and others.

Regional Analysis:

The age related macular degeneration market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas is projected to hold a dominant share of the global market through the forecast period. The rising burden of the disease in the region is expected to drive the proliferation of the regional market. According to the Centers for Disease Control and Prevention (CDC), 1.8 million people were suffering from the disease in 2015 in the U.S.

Europe is an important growth pocket placed at the second position in the marketplace. It is predicted to benefit from rising geriatric population and increasing healthcare expenditure. Meanwhile, Asia Pacific is likely to emerge as the fastest growing regional market for AMD over the assessment period. The factors that are responsible for favoring the expansion of the age-related macular degeneration market in the region are rising healthcare expenditure, increasing prevalence of eye-disorders, growing geriatric population, etc.

Industry News:

In November 2018, the European Court of Justice has determined that Avastin by Roche can be reimbursed for the treatment of age-related macular degeneration despite the challenge imposed by Bayer and Novartis.

In December 2018, the U.S. based Ophthotech Corp. has scrapped the clinical trials of C5 inhibitor for the treatment of wet age-related macular degeneration in spite of successful phase 2a results exhibiting tolerance for imura (avacincaptad pegol) in combination with ranibizumab (Lucentis).

In December 2018, a team of British scientists has announced that they are piloting an eye drop aimed at treating age-related macular degeneration (AMD). The researchers have concluded successful trials on rabbits and pigs and will be tried on human eyes in 2019.

Browse Complete 220 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

         

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Distraction Osteogenesis Devices Market - Granular Market Report and Review, 2018

Market Scenario:

Global Distraction Osteogenesis Devices Market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  

Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6392

Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.

Segmentation

The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.

The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.

Key players

Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.

Regional Market Summary

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.

Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.

The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.

Browse Complete 90 Pages Premium Research Report Enabled with 94 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/distraction-osteogenesis-devices-market-6392           

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Dercum’s Disease Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2023

Market Scenario

The global Dercum’s Disease treatment market is expected to register a significant growth during the forecast period (2018–2023).

Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.

Dercum’s Disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the Dercum’s Disease are often short compared to healthy individuals due to bone anomalies.

Key players

Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis,Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, Amgen, Valeant Pharmaceuticals, Syneron Medical, St. Jude Medical Inc. and Alimed, Inc. are some players in the global dercum’s disease market.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6350

Segmentation

The global dercum’s disease market has been segmented into treatment, distribution channel, and end-user.

The market, on the basis of treatment, has been segmented into surgery, medication, liposuction, electrotherapy, acupuncture, and others. The medication segment has been further segmented into diuretics, non-steroidal anti-inflammatory drugs, corticosteroids, and others.

The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.

The market, by end-user, has been segmented into hospital & clinics, ambulatory surgical centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dercum’s disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European dercum’s disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The dercum’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dercum’s disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global dercum’s disease market owing to a well-established healthcare sector, rising prevalence of rare diseases, and growing healthcare expenditure. According to the data published in the National Center for Biotechnology Information (NCBI) in 2017, about 25 to 30 million American population live with a rare disease. Additionally, favorable reimbursement scenario and a relatively large number of research and development (R&D) activities contribute to the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in the US, the total national health expenditure was USD 3.2 trillion in the year 2015.

Europe is expected to hold the second largest position in the global dercum’s disease market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.

The dercum’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing disposable income, continuously developing economies, and increasing government funding for the healthcare sector. Additionally, regional expansions by market players in the region are considered to be contributing to the market growth.

The Middle East & Africa has the least market share in the global market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dercums-disease-market-6350    

       

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Patellar Tendinitis Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

Increasing prevalence of sports injury, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Furthermore, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases are likely to fuel the market growth during the forecast period. Moreover, increasing geriatric population is boost the market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies. However, side-effects and higher treatment cost may hinder the market growth during the forecast period.

The global patellar tendinitis market is expected to grow at a CAGR of ~8.1% during the forecast period 2017-2023.

Tendons are thick cords that attach the muscles to the bones. Inflammation of these tendons is known as tendinitis. Repetitive movement, injury or diseases conditions are main causes of the tendinitis, with severe pain, swelling or tenderness at the affected area. Use of over-the-counter drugs or pain relievers such as non-steroidal anti-inflammatory drugs (NSAIDs), rest therapy and physical therapy are commonly used treatment measures for this condition. Delayed diagnosis of patellar tendinitis may require a surgery to reduce pain, and improve the movement. Tendinitis is found to be prevalent among athletes or sports players as a result of continuous strain on the tendons due to a rigorous workout, running and other activities. Moreover, patellar tendinitis is an injury to the tendon connecting kneecap (patella). The patellar tendon works with the muscles at the front of the thigh to knee. Patellar tendinitis or tendonitis is also known as jumper's knee and is most common in athletes whose sports involve frequent jumping such as basketball and volleyball. However, even people who don't participate in jumping sports can get patellar tendinitis

Competitive Dashboard:

Some of key the players in the market are Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy) and others.

Segmentations

The global patellar tendinitis market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of the diagnosis, it is segmented into the physical examination, imaging tests, and others. The imaging test is further segmented into X-rays, Ultrasound, and Magnetic resonance imaging (MRI).

The treatment segment is divided into corticosteroid injection, platelet-rich plasma injection, surgery, Medical devices, and others. The medical devices are further segmented into the mechanical band, support tape, pre-cut strips, continuous rolls, and others.

Based on the end user, it is segmented into hospitals & clinics, research laboratories, and others.

Major Regional Analysis:

The Americas dominate the global patellar tendinitis market owing to well-developed technology, increasing patient population for sports injury, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region. 

Europe holds the second position in the global patellar tendinitis market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.    

The Asia Pacific is the fastest growing patellar tendinitis market owing to the presence of rapidly developing healthcare technology and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/patellar-tendinitis-market-5134

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future,

Office No. 528, Amanora Chambers,

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com